OverviewChartNewsTraderScreen

Soc. Generale Knock-Out GNMSF/  DE000CL7HDD0  /

Frankfurt Zert./SG
2024-09-20  4:43:58 PM Chg.-0.490 Bid5:30:44 PM Ask5:30:44 PM Underlying Strike price Expiration date Option type
2.350EUR -17.25% -
Bid Size: -		 -
Ask Size: -		 Genmab A/S 1,571.259 - 2078-12-31 Call
GlobeNewswire 08-19 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire 08-08 Genmab Announces Financial Results for the First Half of 2024
GlobeNewswire 08-08 Genmab Updates 2024 Financial Guidance
GlobeNewswire 08-05 Genmab Takes Full Control of Acasunlimab Development Program
GlobeNewswire 06-28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire 05-21 Genmab Completes Acquisition of ProfoundBio
GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024
GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 04-03 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire 02-14 Genmab Announces Initiation of Share Buy-Back Program
GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report
GlobeNewswire 2023-11-09 Major Shareholder Announcement
GlobeNewswire 2023-11-08 Major Shareholder Announcement
GlobeNewswire 2023-11-07 Genmab Announces Financial Results for the First Nine Months of 2023
GlobeNewswire 2023-10-17 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire 2023-09-25 Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire 2023-09-04 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire 2022-02-24 Notice to Convene the Annual General Meeting of Genmab A/S
GlobeNewswire 2022-02-16 Genmab Publishes 2021 Annual Report
GlobeNewswire 2022-01-25 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
GlobeNewswire 2021-11-10 Genmab Announces Financial Results for the First Nine Months of 2021
GlobeNewswire 2021-11-04 Genmab Improves its 2021 Financial Guidance
GlobeNewswire 2021-10-19 Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire 2021-09-21 Capital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewswire 2021-09-20 Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...